PMID- 18231928
OWN - NLM
STAT- MEDLINE
DCOM- 20080407
LR  - 20211203
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 49
IP  - 2
DP  - 2008 Feb
TI  - Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory 
      primary cutaneous anaplastic large cell lymphoma.
PG  - 359-61
LID - 10.1080/10428190701809214 [doi]
FAU - Chumsri, Saranya
AU  - Chumsri S
FAU - Zhao, Merry
AU  - Zhao M
FAU - Garofalo, Michael
AU  - Garofalo M
FAU - Burger, Angelika
AU  - Burger A
FAU - Hamburger, Anne
AU  - Hamburger A
FAU - Zhao, Frank
AU  - Zhao F
FAU - Rapoport, Aaron
AU  - Rapoport A
LA  - eng
PT  - Case Reports
PT  - Letter
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - Lymphoma, Large-Cell, Anaplastic/*drug therapy
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Protein Kinases/*drug effects
MH  - Salvage Therapy
MH  - Sirolimus/*therapeutic use
MH  - Skin Neoplasms/*drug therapy
MH  - TOR Serine-Threonine Kinases
MH  - Treatment Outcome
EDAT- 2008/01/31 09:00
MHDA- 2008/04/09 09:00
CRDT- 2008/01/31 09:00
PHST- 2008/01/31 09:00 [pubmed]
PHST- 2008/04/09 09:00 [medline]
PHST- 2008/01/31 09:00 [entrez]
AID - 790038947 [pii]
AID - 10.1080/10428190701809214 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2008 Feb;49(2):359-61. doi: 10.1080/10428190701809214.